Emily J. Tremblay is a patent litigator dedicated to protecting and monetizing her clients’ intellectual property and technology, as well as to helping them grow and protect their competitive positions in the markets where they operate. Emily represents clients in complex, multi-million-dollar patent litigation across technologies and the country, including plaintiffs and defendants in the pharmaceutical, medical device, video streaming, semiconductor, and mechanical spaces. She appreciates the dynamic, fast-changing nature of her clients’ industries and enjoys the challenge of leveraging her knowledge of those industries to best protect her clients’ valuable interests.
Emily came to Robins Kaplan after clerking for federal judges for four years, an invaluable experience that she now leverages for her clients.
Served as lead defense counsel for BioDelivery Sciences Int’l, Inc. (BDSI) in two patent litigations, after BDSI was acquired by Collegium Pharmaceutical, Inc. in March of 2022. Cases were pending in the Eastern District of North Carolina where BDSI’s products Bunavail® (buprenorphine and naloxone) buccal film and Belbuca® (buprenorphine) buccal film were accused of infringing Aquestive Therapeutic’s U.S. Patent No. 8,765,167. The parties had been litigating for nearly a decade in federal district courts and in multiple proceedings before the Patent Trial and Appeal Board. After appearing as substitute counsel for BDSI, Robins Kaplan developed and asserted strategic patent infringement defenses and—in a little over eight months—reached a favorable settlement achieving complete freedom to market for BDSI. Aquestive Therapeutics, Inc. v. BioDelivery Sciences Int’l, Inc., Civ. No. 19-505-D (E.D.N.C.); Indivior Inc. v. BioDelivery Sciences Int’l, Inc., Civ. No. 15-350-D (E.D.N.C.)
Trial counsel for Defendants Erie Custom Computer Applications, Inc. and Payroll World, Inc. in a significant software licensing dispute involving claims of copyright infringement, trade secret misappropriation, tortious interference with prospective economic advantage, and breach of contract. Obtained a complete defense verdict in seven-day jury trial leading to dismissal of all claims. MPAY Inc. v. Erie Custom Computer Applications, Inc.
Represented Upsher-Smith Laboratories in Hatch-Waxman litigation concerning five Orange Book-listed patents for the acne drug, Absorica®. Sun Pharmaceutical Industries, Inc. v. Upsher-Smith Laboratories, No. 19-cv-02546 (D.N.J. 2019).
Represented Honeywell International Inc. in a trade secret and breach of contract dispute with Ophir Corporation involving Lidar-based optical air data systems for navigating aircraft. Settled the case on behalf of Honeywell after previously prevailing on a motion for a temporary restraining order/preliminary injunction. The dispute was venued in the United States District Court for the District of Arizona. Ophir Corporation v. Honeywell International Incorporated, No. CV-17-02083-PHX-GMS.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.